跳到正文
原文
Endpoints News 生物医药· Elizabeth Cairns·· 2 天前AI 评分25

Merck 停止开发从 ArQule 获得的 BTK 抑制剂 Nemtabrukinib

Merck ends the sorry saga of BTK inhibitor it got from ArQule

AI 导读

Merck 终止了开发从 ArQule 获得的 BTK 抑制剂 Nemtabrukinib,该药物是 Merck 2019 年以 27 亿美元收购 ArQule 的主要原因。

正文

Mer­ck has end­ed de­vel­op­ment of a BTK in­hibitor that was the main rea­son it bought Ar­Qule for $2.7 bil­lion in 2019.

Nemtabru­ti­nib, or MK-1026, was …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news